In order to demonstrate that the hits identified by these two integrated functional and clinical genomics approaches are potential prostate cancer-specific driver genes, we chose to study KIF4A and WDR62 as they were relatively uncharacterized in the context of mCRPC. This evidence concerns the gene KIF4A and prostate cancer.